TABLE OF CONTENTS As filed with the United States Securities and Exchange Commission on January 29, 2026. Registration Statement No. 333-292790 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AgomAb Therapeutics NV (Exact name of registrant as specified in its charter) 2836 (Primary Standard Industrial Classification Code Number) N/A (I.R.S. Employer Identification Number) (State or Other Jurisdiction ...

Company Overview - InflaRx N.V. is a biopharmaceutical company focused on developing anti-inflammatory therapeutics by targeting the complement system [3] - The company utilizes proprietary anti-C5a and anti-C5aR technologies to create specific inhibitors of the complement activation factor C5a and its receptor [3] - InflaRx's lead program is izicopan (INF904), an orally administered small molecule inhibitor that has shown promising pharmacokinetic and pharmacodynamic characteristics in clinical studies [3] - The company is also developing vilobelimab, a first-in-class anti-C5a monoclonal antibody that has demonstrated clinical activity and tolerability [3] Upcoming Events - InflaRx will participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 on February 11-12, 2026, with a fireside chat scheduled for February 11 at 11:30 AM ET [1] - The company will conduct one-on-one investor meetings on February 11 during the same summit [1] - InflaRx will also present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026, with a virtual presentation on February 25 at 8:40 AM ET [2] - One-on-one investor meetings will also be held on February 25 [2]

Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027 WATERTOWN, Mass., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it recently initiated dosing in its BREADTH Phase 2b clinical tri ...

SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today presented a poster titled "Investigating the Efficacy of Nimacimab Alone or in Combination with Tirzepatide, and as a Maintenance Therapy Post Tirzepatide Discontinuation in a Diet-Induced Obesity (DIO) Mouse Model" at Keystone’s conference, Obesity Therapeutics: Unlocking Benefi ...

Core Insights - The Phase II study of soficitinib, a novel TYK2 inhibitor, shows promising safety and efficacy for treating moderate-to-severe atopic dermatitis (AD) [1][6] Study Design and Results - The study was a double-blind, placebo-controlled trial with 75 participants randomized to receive either soficitinib at 80 mg, 120 mg, or a placebo [2] - The primary endpoint focused on safety and efficacy, with key efficacy measured by the percentage change in Eczema Area and Severity Index (EASI) at week 4 [2] - Soficitinib demonstrated significant efficacy, with percentage improvements in EASI at week 4 being 78.2% for the 80 mg group, 72.5% for the 120 mg group, and 16.7% for the placebo group [3] Efficacy Endpoints - Both soficitinib doses achieved a statistically significant higher EASI-75 response rate of 64.0% compared to a 56.0% difference from placebo [3] - The 80 mg soficitinib group had a greater percentage of patients achieving a Validated Investigator Global Assessment score of 0 or 1, with a 36.0% response rate compared to 4.0% in the placebo group [3] Quality of Life and Pruritus Relief - Soficitinib provided rapid relief from pruritus, with significant improvements observed as early as day 2, peaking at week 4 [4] - In the soficitinib groups, 72.0% of patients achieved an improvement of 4 points or more at week 4, compared to 16.0% in the placebo group [4] Safety Profile - Soficitinib exhibited a favorable safety profile, with treatment-related adverse events being mild or moderate, comparable to placebo [5] - All treatment-emergent adverse events in the 80 mg group were mild [5] Future Development - Patient enrollment for the Phase III clinical trial of soficitinib in AD has been completed, with 579 patients enrolled [8] - Soficitinib is also being developed for other T-cell related autoimmune disorders, including vitiligo, with a Phase II trial completed for 162 patients [8] Company Overview - InnoCare is a biopharmaceutical company focused on developing first-in-class and best-in-class drugs for cancers and autoimmune diseases, with operations in China and the United States [9]

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best inexpensive stocks to buy now. On January 20, Bristol Myers Squibb announced a partnership with Microsoft (NASDAQ:MSFT) to enhance the early detection of lung cancer. The collaboration centers on integrating Bristol Myers’ oncology expertise with Microsoft’s advanced AI-enabled radiology platform. By using these digital tools, the companies aim to streamline the identification of non-small cell lung cancer, ensuring patients are guided toward optim ...

Core Viewpoint - WuXi Biologics and Sinorda Biomedicine have announced a strategic collaboration to develop and manufacture SND006, a novel bispecific antibody aimed at treating inflammatory bowel disease (IBD) and other autoimmune diseases [1][2]. Company Overview - WuXi Biologics is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) that provides end-to-end solutions for biologics from concept to commercialization [4]. - The company employs over 12,000 skilled professionals across multiple countries, including China, the United States, Ireland, Germany, and Singapore [5]. - As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, with 74 in Phase III and 25 in commercial manufacturing [5]. Collaboration Details - Under the agreement, Sinorda Biomedicine will utilize WuXi Biologics' expertise in biologics development to advance SND006's preclinical studies and clinical supply, expediting the Investigational New Drug (IND) application process [2]. - Sinorda Biomedicine has completed in vitro functional validation studies for SND006 and plans to submit IND applications to the National Medical Products Administration (NMPA) in China and the U.S. Food and Drug Administration (FDA) in 2026 [2]. Future Prospects - The collaboration aims to expand further into Sinorda Biomedicine's pipeline, which includes multiple integrated projects from molecule discovery to clinical manufacturing [2]. - Both companies believe that this partnership will accelerate the IND filings of innovative biologics, addressing unmet medical needs in autoimmune diseases [3]. Sinorda Biomedicine Overview - Established in 2010, Sinorda Biomedicine focuses on the R&D and industrialization of innovative drugs for digestive tract diseases, tumor immunity, and autoimmune diseases [8][9]. - The company has successfully commercialized its self-developed drug for gastric acid-related diseases and has ongoing clinical research for solid tumor treatments [10].

IITs represent an important pathway for exploring new drug indications and therapeutic strategies and serve as a key driver of medical innovation. Over the next three years, the Alliance plans to advance 10–20 innovative therapeutic candidates to the proof-of-concept stage in clinical development. Through this platform, Nona Biosciences will gain earlier and deeper insights into unmet clinical needs and access to leading scientific research capabilities, ultimately accelerating the development of innovative ...

Core Viewpoint - Altimmune Inc has announced a $75 million registered direct offering of common stock, leading to a significant decline in its share price [1][9]. Group 1: Offering Details - The company has entered a securities purchase agreement for the sale of 17,045,454 shares of common stock, or pre-funded warrants [2]. - The offering is expected to generate approximately $75 million in gross proceeds, priced at about $4.40 per share, and is anticipated to close around January 29, subject to customary conditions [3]. Group 2: Use of Proceeds - Net proceeds from the offering will be used to fund preparations for the upcoming Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH), along with working capital and general corporate purposes [4]. Group 3: Stock Performance - Currently, Altimmune's stock is trading 17.4% above its 20-day simple moving average and 19.8% above its 100-day simple moving average, indicating short-term strength despite the recent decline [5]. - Over the past 12 months, shares have decreased by approximately 26.33% and are closer to their 52-week lows than highs [5]. - The stock's RSI is at 78.59, indicating overbought territory, while the MACD shows bullish momentum, suggesting a potential correction may be due [6]. Group 4: Company Overview - Altimmune is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases, with its product candidate pemvidutide being a dual receptor agonist currently in clinical development [7]. - The recent stock offering is significant as it aims to fund further development of pemvidutide, which could address major health issues [8].

BERKELEY HEIGHTS, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company developing differentiated therapies for retinal diseases, today announced that clinical data from its Phase 1 study of TH103 will be presented at the 49th Annual Meeting of the Macula Society, taking place February 25-28 in San Diego, California. TH103 is a novel investigational therapy engineered by VEGF scientific pioneer Dr. Napoleone Ferrara to achie ...